Hypercalcemia Treatment Market is Estimated to Witness High Growth Owing to Growing Prevalence of Hyperparathyroidism and Launch of Novel Therapies
The hypercalcemia treatment market is estimated to be valued at USD 4.32 Bn in 2024, exhibiting a CAGR of 8.4% over the forecast period (2024-2031). Rising burden of primary hyperparathyroidism worldwide is a key factor driving the demand for hypercalcemia treatment drugs. Furthermore, launch of novel drugs with improved efficacy and safety is expected to boost the market growth during the forecast period.
Market Dynamics:
The hypercalcemia treatment market is primarily driven by the growing prevalence of hyperparathyroidism across the globe. Primary hyperparathyroidism is one of the most common endocrine disorders worldwide. Rising geriatric population which is at high risk of hyperparathyroidism acts as a high impact driver.
Another key factor is the launch of new drug entities offering advantages over existing therapies. For instance, in 2021, Amgen Inc., a pharmaceutical company, received the U.S. Food and Drug Administration approval for its Parsabiv (etelcalcetide) for secondary hyperparathyroidism in patients with chronic kidney disease on hemodialysis. Compared to traditional calcimimetics, Parsabiv demonstrated improved efficacy and convenience of thrice-weekly dosing.
Increasing Prevalence of Hypercalcemia
One of the major drivers fueling the growth of the hypercalcemia treatment market is the rising prevalence of hypercalcemia globally. Hypercalcemia commonly occurs as a complication of various cancers and other chronic diseases. With the increasing burden of cancer and other endocrine disorders worldwide, the incidence of hypercalcemia has also risen significantly in recent years. This high prevalence of the condition is driving greater demand for effective hypercalcemia treatment solutions.
Growing Awareness and Diagnosis Rates
Improved awareness among patients and physicians about the symptoms and risks of hypercalcemia is another key factor positively impacting the market. Earlier, hypercalcemia could go undiagnosed for long periods. However, with enhanced education and diagnostic capabilities, today cases are being identified much earlier. This allows for the timely intervention and management of hypercalcemia, preventing further complications. Various government and non-profit initiatives to spread awareness about hypercalcemia diagnosis and management have contributed to the market growth.
Stringent Regulatory Environment
Pharmaceutical companies developing new drug candidates for hypercalcemia treatment have to navigate a stringent regulatory landscape. The approval process for these drugs is complex and lengthy since hypercalcemia is usually a complication of other serious illnesses. Regulators closely scrutinize the safety, efficacy, and quality of new molecular entities given their intended use in critically-ill patients. This regulatory bottleneck poses a challenge for quick market entry of novel hypercalcemia medications.
Availability of Generic Drugs
A dominant restraint is the availability of affordable generic drugs to manage hypercalcemia symptoms. Many hypercalcemia drugs including bisphosphonates have gone off-patent, allowing the production of much cheaper generic versions. While it increases treatment access, price competition from these generics poses pricing pressures on branded formulations. This impacts the revenues of major players investing in proprietary hypercalcemia drug R&D.
Scope for Combination Therapies
Given the multifactorial etiology of hypercalcemia in most cases, experts believe combination drug regimens could offer better outcomes than monotherapies. This represents a lucrative opportunity for companies to develop and market fixed-dose combination medications targeting different pathophysiological mechanisms of the condition. Successful combination therapies can capture a bigger market share and boost long-term sales potentials.
Emerging Economies with Large Patient Populations
Hypercalcemia worldwide incidence is projected to rise faster in developing Asian, African, and Latin American countries where cancer rates are surging. At the same time, diagnostic capacities are also improving in these emerging healthcare markets. This access to a huge latent and currently undiagnosed hypercalcemia patient pool provides significant opportunities for pharmaceutical firms and medical device manufacturers to strengthen their presence. Novel solutions tailored for resource-limited settings can be highly lucrative in these markets.
Link: https://www.coherentmarketinsights.com/market-insight/hypercalcemia-treatment-market-3504
Key Developments
- On August 12, 2024, Ascendis Pharma A/S, a pharmaceutical company, announced that the U.S. Food & Drug Administration (FDA) approved YORVIPATH (palopegteriparatide; developed as TransCon PTH) for the treatment of hypoparathyroidism in adults. YORVIPATH is a prodrug of parathyroid hormone (PTH [1-34]), administered once daily, and designed to provide continuous exposure to released PTH over the 24-hour dosing period. Hypoparathyroidism is a rare endocrine disease caused by insufficient levels of parathyroid hormone that impacts multiple organs.
Key Players
Pfizer, Inc., Ascendis Pharma, Amgen Inc., Cipla, Hikma Pharmaceuticals, PLC, Apotex Inc., Mylan N.V., Sun Pharmaceutical Industries Ltd., Novartis AG, Dr. Reddy's Laboratories Ltd., Glenmark Pharmaceuticals Ltd., Sumitomo Pharma Co., Ltd., Alkem Labs, and Crinetics Pharmaceuticals, Inc.
